^
Association details:
| Biomarker: | FLT3-TKD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | crenolanib (ARO-002) (FLT3 inhibitor, PDGFR α inhibitor, PDGFR β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML
Published date:
05/26/2022
Excerpt:
Crenolanib maintenance therapy was offered...33 (75%) pts had FLT3-ITD, 8 (18%) had TKD, and 3 (7%) had ITD and TKD mutations. 11 pts had concomitant NPM1/DNMT3A mutations...11 pts had concomitant NPM1/DNMT3A mutations...CRc rates > 80% were noted in pts ≤ 60 yo, FLT3-ITD mutations, concomitant FLT3/DMT3A/NPM1 mutations...Long-term outcomes of a phase 2 trial of crenolanib combined with 7+3 induction and consolidation in adults with newly diagnosed FLT3 mutant AML demonstrate high response rates (CRc 86%).
Secondary therapy:
cytarabine + daunorubicin; cytarabine
DOI:
10.1200/JCO.2022.40.16_suppl.7007
Trial ID:
